Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | LIPE | Q05469 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.32 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24120035 | 0.78 | LIPE (0.38) | HSP90AA1LIPEKMT2APKMPOLB | |
| SCHEMBL26287179 | 0.76 | — | — | |
| SCHEMBL9737159 | 0.76 | ALDH1A1 (0.40) | KMT2APOLBTP53LMNAALDH1A1 | |
| SCHEMBL362028 | 0.76 | PKM (0.40) | HSP90AA1LIPEKMT2APKMPOLB | |
| SCHEMBL1053984 | 0.74 | LIPE (0.36) | HSP90AA1LIPEKMT2APKMPOLB | |
| SCHEMBL15334705 | 0.74 | LIPE (0.36) | HSP90AA1LIPEKMT2APKMPOLB | |
| SCHEMBL1053985 | 0.74 | ALDH1A1 (0.37) | HSP90AA1LIPEKMT2APKMPOLB | |
| SCHEMBL12012145 | 0.74 | LIPE (0.36) | HSP90AA1LIPEKMT2APKMPOLB | |
| SCHEMBL423024 | 0.74 | LIPE (0.36) | HSP90AA1LIPEKMT2APKMPOLB | |
| SCHEMBL12751023 | 0.74 | LIPE (0.36) | HSP90AA1LIPEKMT2APKMPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3560497-A1 | COMPOSITIONS AND METHODS FOR DRUG-SENSITIZATION OR INHIBITION OF A CANCER CELL | The Texas A&M University System (US) | 2019-10-30 | — | — | EP | disclosed |
| US-20190142817-A1 | COMPOSITIONS AND METHODS FOR DRUG SENSITIZATION OF PARASITES | THE TEXAS A&M UNIVERSITY SYSTEM | 2019-05-16 | — | — | US | disclosed |
| EP-2890374-B1 | COMPOSITIONS AND METHODS FOR DRUG-SENSITIZATION OR INHIBITION OF A CANCER CELL | TEXAS A & M UNIV SYS (US) | 2019-04-03 | — | — | EP | disclosed |
| US-10226455-B2 | Compositions and methods for drug sensitization of parasites | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2019-03-12 | — | — | US | disclosed |
| US-9867807-B2 | Compositions and methods for drug-sensitization or inhibition of a cancer cell | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2018-01-16 | — | — | US | disclosed |
| US-20170071905-A1 | COMPOSITIONS AND METHODS FOR DRUG-SENSITIZATION OR INHIBITION OF A CANCER CELL | THE TEXAS A&M UNIVERSITY SYSTEM | 2017-03-16 | — | — | US | disclosed |
| US-9539237-B2 | Compositions and methods for drug-sensitization or inhibition of a cancer cell | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2017-01-10 | — | — | US | disclosed |
| EP-3107537-A1 | COMPOSITIONS AND METHODS FOR DRUG SENSITIZATION OF PARASITES | The Texas A&M University System (US) | 2016-12-28 | — | — | EP | disclosed |
| US-20160354358-A1 | COMPOSITIONS AND METHODS FOR DRUG SENSITIZATION OF PARASITES | THE TEXAS A&M UNIVERSITY SYSTEM | 2016-12-08 | — | — | US | disclosed |
| US-20160038460-A1 | COMPOSITIONS AND METHODS FOR DRUG-SENSITIZATION OR INHIBITION OF A CANCER CELL | THE TEXAS A&M UNIVERSITY SYSTEM | 2016-02-11 | — | — | US | disclosed |
| EP-2027132-B1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| CN-101448844-A | Thiazolo-pyramidine / pyridine urea derivatives as adenosine a2b receptor antagonists | HOFFMANN LA ROCHE (CH) | 2009-06-03 | — | — | CN | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
| EP-2027132-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007134958-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007134958-A1 | THIAZOLO-PYRAMIDINE / PYRIDINE UREA DERIVATIVES AS ADENOSINE A2B RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-29 | — | — | WO | disclosed |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | BRINKMAN JOHN A | 2007-11-22 | — | — | US | disclosed |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | BRINKMAN JOHN A | 2007-11-22 | — | — | US | disclosed |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | BRINKMAN JOHN A | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160354358-A1 | COMPOSITIONS AND METHODS FOR DRUG SENSITIZATION OF PARASITES | ABCC1, SLC11A2, ABCB11 | HSP90AA1 102/4885LIPE 3951/4885KMT2A 4104/4885 |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | HSP90AA1 154/4885LIPE 2921/4885KMT2A 1844/4885 |
| US-20070270433-A1 | Thiazolo-pyrimidine/pyridine urea derivatives | ADORA2B, UTS2R, TBXA2R | HSP90AA1 3712/4885LIPE 2963/4885KMT2A 3413/4885 |
| US-10226455-B2 | Compositions and methods for drug sensitization of parasites | ABCC1, SLC11A2, ABCB11 | HSP90AA1 102/4885LIPE 3951/4885KMT2A 4104/4885 |
| US-20170071905-A1 | COMPOSITIONS AND METHODS FOR DRUG-SENSITIZATION OR INHIBITION OF A CANCER CELL | ROS1, ABCC1, NQO1 | HSP90AA1 263/4885LIPE 4476/4885KMT2A 3884/4885 |
| US-20190142817-A1 | COMPOSITIONS AND METHODS FOR DRUG SENSITIZATION OF PARASITES | ABCC1, SLC11A2, ABCB11 | HSP90AA1 102/4885LIPE 3951/4885KMT2A 4104/4885 |
| US-20160038460-A1 | COMPOSITIONS AND METHODS FOR DRUG-SENSITIZATION OR INHIBITION OF A CANCER CELL | ROS1, ABCC1, NQO1 | HSP90AA1 263/4885LIPE 4476/4885KMT2A 3884/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | HSP90AA1 154/4885LIPE 2921/4885KMT2A 1844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.